- 大麻會在 12月31日 前重新分類嗎？11¢11%
The DEA administrative process for moving botanical marijuana from Schedule I to Schedule III remains in a limited briefing phase following an October 22 order from Chief ALJ Derek Julius. That ruling admitted a September GAO report highlighting gaps in federal scheduling procedures but denied requests to reopen the June-July 2026 hearings for additional testimony. Optional briefs on the report’s weight are due by November 5, after which the stay lifts and the judge can issue a nonbinding recommendation. An April 2026 Attorney General order already placed state-licensed medical marijuana and FDA-approved products into Schedule III, with the DEA issuing initial federal registrations to over 900 dispensaries in seven states as the first implementation step. Broader rescheduling covering adult-use cannabis requires the full hearing record, agency decision, and potential further review, keeping near-term resolution unlikely.
規則
如果美國緝毒局（https://www.dea.gov/drug-information/drug-scheduling）在 2026年12月31日 下午11:59 ET 前將大麻從附表 I 降級至任何其他級別（或完全取消管制），此市場將判定為「是」。否則，此市場將以「否」結算。 此市場判定的主要依據為美國政府的官方資訊，但也會參考可信報導所形成的共識。
機器翻譯。如有爭議，以原文為準。